Seeking novel treatments for Complement-related diseases including age-related macular degeneration (AMD) and creation of spin out company Complement Therapeutics

Narrative

In March 2020, the spin out company Complement Therapeutics was formed based on our research into the ways the Complement System (also known as the complement cascade) which is part of the immune system) works, and how it is dysregulated in age-related macular degeneration. Complement Therapeutics aims to develop innovative and effective therapies to address unmet needs in complement mediated diseases such as dry AMR which affects millions and for which there is currently no effective treatment.

In February 2022, the company secured SEED financing and is currently developing it lead asset. www.complementtx.com

Impact date	2019
Category of impact	Health and wellbeing, Economic
Impact level	Engagement